| Index | — | P/E | — | EPS (ttm) | -1.20 | Insider Own | 33.35% | Shs Outstand | 99.15M | Perf Week | 3.08% |
| Market Cap | 332.14M | Forward P/E | — | EPS next Y | -0.70 | Insider Trans | -0.32% | Shs Float | 57.22M | Perf Month | 18.37% |
| Enterprise Value | 201.14M | PEG | — | EPS next Q | -0.18 | Short Float | 13.09% | Perf Quarter | -21.91% | ||
| Income | -90.00M | P/S | 19.54 | EPS this Y | — | Short Ratio | 8.94 | Perf Half Y | -20.43% | ||
| Sales | 17.00M | P/B | 2.14 | EPS next Y | — | ROA | -35.62% | Short Interest | 7.49M | Perf YTD | -16.25% |
| Book/sh | 1.56 | P/C | 1.60 | EPS next 5Y | — | ROE | -63.05% | 52W High | 4.83 -30.64% | Perf Year | -16.04% |
| Cash/sh | 2.10 | P/FCF | — | EPS past 3/5Y | — | ROIC | -37.53% | 52W Low | 2.43 37.86% | Perf 3Y | -85.29% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — 63.45% | Gross Margin | 81.22% | Volatility | 8.08% 7.26% | Perf 5Y | -97.46% |
| Dividend TTM | — | EV/Sales | 11.83 | EPS Y/Y TTM | — | Oper. Margin | -554.71% | ATR (14) | 0.23 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 11.02 | Sales Y/Y TTM | -48.48% | Profit Margin | -568.80% | RSI (14) | 60.33 | Recom | 2.08 |
| Dividend Gr. 3/5Y | — | Current Ratio | 11.30 | EPS Q/Q | 96.25% | SMA20 | 12.59% | Beta | 0.46 | Target Price | 11.50 |
| Payout | 0.00% | Debt/Eq | 0.50 | Sales Q/Q | 350.00% | SMA50 | 1.11% | Rel Volume | 0.60 | Prev Close | 3.35 |
| Employees | 45 | LT Debt/Eq | 0.50 | Earnings | Nov 04 | SMA200 | -11.84% | Avg Volume | 865.44K | Price | 3.35 |
| IPO Date | Nov 16, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 26.14% 263.88% | Net Debt/EBITDA | — | Volume | 521,958 | Change | 0.00% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-10-26 | Initiated | Wells Fargo | Overweight | $11 |
| Jun-02-26 | Initiated | Leerink | Outperform | $12 |
| Mar-09-26 | Initiated | Guggenheim | Buy | $12 |
| Dec-05-25 | Reiterated | Stifel Nicolaus | $7.50 → $10 | |
| Nov-05-25 | Reiterated | Stifel Nicolaus | $9.00 → $7.50 | |
| Aug-29-25 | Reiterated | Stifel Nicolaus | $9.00 | |
| Aug-13-25 | Reiterated | HC Wainwright & Co. | Buy | $5.00 → $3.50 |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral | |
| Dec-22-22 | Reiterated | Cantor Fitzgerald | Overweight | $3.00 |
| Nov-30-22 | Reiterated | HC Wainwright & Co. | Buy | $5.00 |
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 17 | 35 | 3 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 3 | 6 | 1 | 0 | — | — | — | — | — | |
| Gross Profit | 12 | 29 | 2 | 0 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 35 | 44 | 62 | 36 | — | — | — | — | — | |
| Research and Development | 65 | 72 | 82 | 72 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | -106 | 0 | — | — | — | — | — | |
| Operating Income | -88 | -87 | -36 | -108 | — | — | — | — | — | |
| Interest Expense | 8 | 9 | 9 | 6 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 6 | 17 | 8 | 12 | — | — | — | — | — | |
| Net Income Before Taxes | -90 | -79 | -37 | -101 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -90 | -79 | -37 | -101 | — | — | — | — | — | |
| Net Income From Continuing Operations | -90 | -79 | -37 | -101 | — | — | — | — | — | |
| Net Income | -90 | -79 | -37 | -101 | — | — | — | — | — | |
| EPS (Recurring) | -1.20 | -1.87 | -5.59 | -17.07 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.20 | -1.87 | -5.59 | -17.07 | — | — | — | — | — | |
| EPS (Diluted) | -1.20 | -1.87 | -5.59 | -17.07 | — | — | — | — | — | |
| EBITDA | -80 | -69 | -28 | -95 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 24.83 | 4.80 | 51.36 | — | — | — | — | — | — | |
| Gross Margin | 70.59 | 82.86 | 66.67 | — | — | — | — | — | — | |
| Operating Margin | -517.65 | -248.57 | -1,200.00 | — | — | — | — | — | — | |
| Net Margin | -529.41 | -225.71 | -1,233.33 | — | — | — | — | — | — | |
| Shares Outstanding | 126 | 42 | 7 | 6 | — | — | — | — | — | |
| Market Capitalization | 422 | 168 | 154 | 151 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Craig Adam R | Executive Chairman | Oct 16 '26 | Buy | 2.58 | 4,600 | 11,884 | 333,251 | Oct 19 |
| KIRSKE DAVID | Chief Financial Officer | Oct 01 '26 | Sale | 2.86 | 11,767 | 33,658 | 155,983 | Oct 05 |
| Volpone John | President | Aug 12 '26 | Sale | 4.44 | 24,576 | 109,228 | 265,305 | Aug 13 |
| Craig Adam R | Executive Chairman | Aug 12 '26 | Sale | 4.44 | 47,436 | 210,829 | 328,651 | Aug 13 |
| KIRSKE DAVID | Chief Financial Officer | Jun 30 '26 | Sale | 4.26 | 8,543 | 36,428 | 167,750 | Jul 01 |
| KIRSKE DAVID | Chief Financial Officer | May 12 '26 | Sale | 4.29 | 16,961 | 72,820 | 176,293 | May 13 |
| Craig Adam R | Executive Chairman | Oct 23 '25 | Buy | 2.90 | 86,206 | 249,997 | 376,087 | Oct 27 |
| Baldry Mark | Chief Commercial Officer | May 16 '25 | Buy | 2.48 | 1,032 | 2,561 | 25,337 | May 20 |
| Baldry Mark | Chief Commercial Officer | Nov 15 '24 | Buy | 0.34 | 13,404 | 4,598 | 129,173 | Feb 14 |
| Baldry Mark | Chief Commercial Officer | May 17 '24 | Buy | 0.68 | 21,646 | 14,654 | 115,769 | Feb 14 |
| Ragan Paula | President and CEO | Jan 24 '25 | Sale | 0.45 | 76,473 | 34,719 | 1,087,386 | Jan 27 |
| Mostafa Adam S. | Chief Financial Officer | Jan 24 '25 | Sale | 0.45 | 74,773 | 33,947 | 0 | Jan 27 |
| Baldry Mark | Chief Commercial Officer | Jan 24 '25 | Sale | 0.45 | 29,159 | 13,241 | 94,123 | Jan 27 |
| DiBiase Mary | Chief Operating Officer | Jan 24 '25 | Sale | 0.45 | 22,258 | 10,094 | 490,980 | Jan 27 |
| Arbet-Engels Christophe | Chief Medical Officer | Jan 24 '25 | Sale | 0.45 | 11,624 | 5,284 | 14,207 | Jan 27 |